GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IR Biosciences Holdings Inc (GREY:IRBS) » Definitions » EV-to-EBITDA

IR Biosciences Holdings (IR Biosciences Holdings) EV-to-EBITDA : 0.00 (As of Jun. 16, 2024)


View and export this data going back to . Start your Free Trial

What is IR Biosciences Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IR Biosciences Holdings's enterprise value is $0.00 Mil. IR Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2010 was $-3.56 Mil. Therefore, IR Biosciences Holdings's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for IR Biosciences Holdings's EV-to-EBITDA or its related term are showing as below:

IRBS's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.48
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-16), IR Biosciences Holdings's stock price is $6.0E-5. IR Biosciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2010 was $-0.350. Therefore, IR Biosciences Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


IR Biosciences Holdings EV-to-EBITDA Historical Data

The historical data trend for IR Biosciences Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IR Biosciences Holdings EV-to-EBITDA Chart

IR Biosciences Holdings Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.40 -1.54 -0.92 -1.92 -1.35

IR Biosciences Holdings Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IR Biosciences Holdings's EV-to-EBITDA

For the Biotechnology subindustry, IR Biosciences Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IR Biosciences Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IR Biosciences Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IR Biosciences Holdings's EV-to-EBITDA falls into.



IR Biosciences Holdings EV-to-EBITDA Calculation

IR Biosciences Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-3.558
=0.00

IR Biosciences Holdings's current Enterprise Value is $0.00 Mil.
IR Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IR Biosciences Holdings  (GREY:IRBS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

IR Biosciences Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.0E-5/-0.350
=At Loss

IR Biosciences Holdings's share price for today is $6.0E-5.
IR Biosciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.350.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


IR Biosciences Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IR Biosciences Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


IR Biosciences Holdings (IR Biosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
8777 E. Via De Ventura, Suite 280, Scottsdale, AZ, USA, 85258
IR Biosciences Holdings Inc is a development-stage biotechnology company engaged in the research & development of potential drug candidate, Homspera and its derivatives, Radilex and Viprovex through its subsidiary, ImmuneRegen BioSciences, Inc. It is engaged in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia.

IR Biosciences Holdings (IR Biosciences Holdings) Headlines

No Headlines